Skip to content
type1.science
Phase 3RecruitingNCT07222137

BARICADE-DELAY: Baricitinib to delay stage-3 T1D

Phase-3 trial testing whether oral baricitinib can delay progression to clinical stage-3 T1D in at-risk stage-1b/2 children and adults.

Primary endpoints

  • Time to stage-3 type 1 diabetes diagnosis

Results so far

No results posted. Live-checked 27 August 2026 (ClinicalTrials.gov last update 25 August 2026): still recruiting; estimated n=150; estimated primary completion July 2031.

The full picture

BARICADE-DELAY is the trial that can move baricitinib from "new-onset preservation" toward actual prevention: the primary endpoint is time to stage-3 diagnosis.